Bicyclic azaheterocyclobenzylamines as PI3K inhibitors

A compound of Formula II:

• or a pharmaceutically acceptable salt thereof, wherein:
• V is CH2;
• T is CH2, or CH(CH3);
• Q is CH2, CH(CH3), or CH(CH2CH3);
• U is O;
• R1 is C1-3 alkyl;
• R3b is H, Cy, —(C1-3alkylene)-Cy, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C(═O)Rb, C(═O)NRcRd, C(═O)ORa, S(═O)2Rb, or S(═O)2NRcRd;
• wherein said C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are optionally substituted by 1, 2, 3, or 4 independently selected R13b groups;
• R4 is H, halo, OH, CN, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, or C1-4 haloalkoxy;
• R5 is halo, OH, CN, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, or cyclopropyl;
• R6 is H;
• R8 is H, halo, —OH, —CN, C1-6 alkyl, or C1-6 haloalkyl;
• R10 is H or C1-4 alkyl;
• each R11 is independently selected from halo, OH, NO2, CN, C1-3 alkyl, C1-3 haloalkyl, C1-3 alkoxy, C1-3 haloalkoxy, amino, C1-3 alkylamino, di(C1-3 alkyl)amino, carbamyl, C1-3 alkylcarbamyl, and di(C1-3 alkyl)carbamyl;
• each R13b is independently selected from halo, CN, NO2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, ORa1, SRa1, C(═O)Rb1, C(═O)NRc1Rd1, C(═O)ORa1, OC(═O)Rb1, OC(═O)NRc1Rd1, NRc1Rd1, NRc1C(═O)Rb1, NRc1S(═O)Rb1, NRc1S(═O)2NRc1Rd1, S(═O)Rb1, S(═O)2Rb1, and S(═O)2NRc1Rd1;
• wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl are each optionally substituted with 1, 2, or 3 independently selected R11 groups;
• each Cy is independently selected from C3-7 cycloalkyl, 4-10 membered heterocycloalkyl, phenyl, and 5-10 membered heteroaryl, wherein said C3-7 cycloalkyl, 4-10 membered heterocycloalkyl, phenyl, and 5-10 membered heteroaryl are optionally substituted with 1, 2, 3, or 4 independently selected R13b groups;
• each Ra, Rc, and Rd is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, and Cy;
• wherein said C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2, or 3 independently selected R13b groups;
• each Rb is independently selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, and Cy;
• wherein said C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2, or 3 independently selected R13b groups;
• or
• each Ra1, Rc1, and Rd1 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl;
• wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl are each optionally substituted with 1, 2, or 3 independently selected R11 groups;
• and
• each Rb1 is independently selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl;
• wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl are each optionally substituted with 1, 2, or 3 independently selected R11 groups.